Global Long-acting PrEP Market Growth 2026-2032
Description
The global Long-acting PrEP market size is predicted to grow from US$ 305 million in 2025 to US$ 834 million in 2032; it is expected to grow at a CAGR of 15.7% from 2026 to 2032.
Long-acting PrEP refers to HIV pre-exposure prophylaxis delivered through formulations or delivery systems that sustain protective drug exposure over extended periods, shifting prevention from daily or event-driven pill-taking to dosing or device replacement at monthly, quarterly, semiannual, or even longer intervals. The primary problem it addresses is the real-world persistence and access gap seen with oral PrEP: many people who would benefit from prevention struggle with continuous daily adherence, timely refills, discreet storage and use, or consistent engagement with care, and fluctuating risk patterns can make stop–start cycles especially prone to protection gaps. By reducing dosing frequency and the day-to-day behavioral burden, long-acting PrEP aims to increase the likelihood of uninterrupted protection while enabling prevention to be packaged more naturally with follow-up, testing, and broader sexual health services. Its product history can be viewed in stages: oral PrEP first established efficacy and became embedded in guidelines and practice; the field then leveraged advances from long-acting HIV treatment—such as micro-/nano-crystal depot technologies, stable injectable formulations, aseptic manufacturing, and cold-chain logistics—to enable the first wave of long-acting PrEP commercialization; and current development is focused on extending duration and diversifying modalities, including longer-interval small-molecule injections, controlled-release implants, and biologics-based approaches with the potential for even less frequent administration. Upstream, long-acting PrEP depends on both conventional pharmaceutical inputs and a more demanding formulation-and-device supply chain: APIs and key intermediates; chemical reagents, catalysts, and solvents; injection- or implant-grade excipients (surfactants, stabilizers, buffers, water for injection, and medical-grade polymers); and the components and consumables required for aseptic production and delivery (injectable-grade glass containers, elastomer stoppers/plungers, seals, needles and safety injection devices, prefilled systems, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish, sterilization validation, temperature-controlled transport, and quality-system services.In 2025, the global production capacity of long-acting PrEP reached 150,000 doses, while total sales amounted to 117,200 doses. The average selling price was USD 2,660 per dose, and manufacturers’ gross margins ranged between 60% and 70%.
The current long-acting PrEP market is characterized by rising awareness and uneven delivery capacity. Clinical and public health stakeholders increasingly view long-acting options as essential for reaching people who struggle with persistence on oral regimens, yet uptake is often constrained by the practical realities of care delivery—reliable follow-up pathways, standardized testing and risk assessment, trained personnel, and tighter inventory and cold-chain discipline. Differences across countries and regions in reimbursement design, provider networks, stigma, and access for priority populations create markedly different adoption trajectories. As a result, competition today is as much about building a sustainable service model as it is about the medicine itself: streamlined patient journeys, integration with sexual health services, community-based outreach, and models tailored to younger or highly mobile groups.
Looking forward, the market is likely to evolve through a combination of technology diversification and service decentralization. On the technology side, development efforts are converging on longer dosing intervals, fewer touchpoints with the health system, improved tolerability, and more flexible user options, with multiple modalities advancing in parallel and enabling differentiated product portfolios. In parallel, real-world success will depend increasingly on complementary delivery innovations—risk-stratified follow-up that avoids unnecessary visits, expanded roles for community providers and pharmacies, digital support for continuity, and smoother “start–pause–restart” pathways. The market will also become more segmented, with different prevention packages emerging for different exposure patterns and social contexts, shifting differentiation from efficacy alone toward sustained user experience and system efficiency.
Key drivers include the alignment of public health priorities with user preferences for prevention that is easier to maintain and more discreet, along with steady progress in formulation and manufacturing that supports broader scale-up. Payers and providers also have growing incentives to adopt models that emphasize outcomes and continuity rather than repeated transactional visits. At the same time, barriers remain substantial: reliance on clinical infrastructure can slow decentralization, concerns about long drug “tail,” injection-site effects, and reversibility can deter initiation for some, and stigma and privacy dynamics continue to influence both demand and engagement. Supply-side complexity—aseptic manufacturing, cold-chain logistics, and reliable component availability—adds another layer of fragility. Ultimately, expansion is likely to be strongest where payment policy, delivery networks, and community engagement reinforce one another, enabling long-acting prevention to function as a durable system rather than a standalone intervention.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting PrEP Industry Forecast” looks at past sales and reviews total world Long-acting PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting PrEP sales for 2026 through 2032. With Long-acting PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting PrEP industry.
This Insight Report provides a comprehensive analysis of the global Long-acting PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting PrEP market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting PrEP.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting PrEP market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Cabotegravir
Lenacapavir
Other
Segmentation by Dosing Interval:
Short-interval Injections
Monthly Injections
Quarterly Injections
Segmentation by Drug Properties:
Original Drug
Generic Drug
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Gilead Sciences
ViiV Healthcare
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting PrEP market?
What factors are driving Long-acting PrEP market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting PrEP market opportunities vary by end market size?
How does Long-acting PrEP break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Long-acting PrEP refers to HIV pre-exposure prophylaxis delivered through formulations or delivery systems that sustain protective drug exposure over extended periods, shifting prevention from daily or event-driven pill-taking to dosing or device replacement at monthly, quarterly, semiannual, or even longer intervals. The primary problem it addresses is the real-world persistence and access gap seen with oral PrEP: many people who would benefit from prevention struggle with continuous daily adherence, timely refills, discreet storage and use, or consistent engagement with care, and fluctuating risk patterns can make stop–start cycles especially prone to protection gaps. By reducing dosing frequency and the day-to-day behavioral burden, long-acting PrEP aims to increase the likelihood of uninterrupted protection while enabling prevention to be packaged more naturally with follow-up, testing, and broader sexual health services. Its product history can be viewed in stages: oral PrEP first established efficacy and became embedded in guidelines and practice; the field then leveraged advances from long-acting HIV treatment—such as micro-/nano-crystal depot technologies, stable injectable formulations, aseptic manufacturing, and cold-chain logistics—to enable the first wave of long-acting PrEP commercialization; and current development is focused on extending duration and diversifying modalities, including longer-interval small-molecule injections, controlled-release implants, and biologics-based approaches with the potential for even less frequent administration. Upstream, long-acting PrEP depends on both conventional pharmaceutical inputs and a more demanding formulation-and-device supply chain: APIs and key intermediates; chemical reagents, catalysts, and solvents; injection- or implant-grade excipients (surfactants, stabilizers, buffers, water for injection, and medical-grade polymers); and the components and consumables required for aseptic production and delivery (injectable-grade glass containers, elastomer stoppers/plungers, seals, needles and safety injection devices, prefilled systems, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish, sterilization validation, temperature-controlled transport, and quality-system services.In 2025, the global production capacity of long-acting PrEP reached 150,000 doses, while total sales amounted to 117,200 doses. The average selling price was USD 2,660 per dose, and manufacturers’ gross margins ranged between 60% and 70%.
The current long-acting PrEP market is characterized by rising awareness and uneven delivery capacity. Clinical and public health stakeholders increasingly view long-acting options as essential for reaching people who struggle with persistence on oral regimens, yet uptake is often constrained by the practical realities of care delivery—reliable follow-up pathways, standardized testing and risk assessment, trained personnel, and tighter inventory and cold-chain discipline. Differences across countries and regions in reimbursement design, provider networks, stigma, and access for priority populations create markedly different adoption trajectories. As a result, competition today is as much about building a sustainable service model as it is about the medicine itself: streamlined patient journeys, integration with sexual health services, community-based outreach, and models tailored to younger or highly mobile groups.
Looking forward, the market is likely to evolve through a combination of technology diversification and service decentralization. On the technology side, development efforts are converging on longer dosing intervals, fewer touchpoints with the health system, improved tolerability, and more flexible user options, with multiple modalities advancing in parallel and enabling differentiated product portfolios. In parallel, real-world success will depend increasingly on complementary delivery innovations—risk-stratified follow-up that avoids unnecessary visits, expanded roles for community providers and pharmacies, digital support for continuity, and smoother “start–pause–restart” pathways. The market will also become more segmented, with different prevention packages emerging for different exposure patterns and social contexts, shifting differentiation from efficacy alone toward sustained user experience and system efficiency.
Key drivers include the alignment of public health priorities with user preferences for prevention that is easier to maintain and more discreet, along with steady progress in formulation and manufacturing that supports broader scale-up. Payers and providers also have growing incentives to adopt models that emphasize outcomes and continuity rather than repeated transactional visits. At the same time, barriers remain substantial: reliance on clinical infrastructure can slow decentralization, concerns about long drug “tail,” injection-site effects, and reversibility can deter initiation for some, and stigma and privacy dynamics continue to influence both demand and engagement. Supply-side complexity—aseptic manufacturing, cold-chain logistics, and reliable component availability—adds another layer of fragility. Ultimately, expansion is likely to be strongest where payment policy, delivery networks, and community engagement reinforce one another, enabling long-acting prevention to function as a durable system rather than a standalone intervention.
LP Information, Inc. (LPI) ' newest research report, the “Long-acting PrEP Industry Forecast” looks at past sales and reviews total world Long-acting PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting PrEP sales for 2026 through 2032. With Long-acting PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long-acting PrEP industry.
This Insight Report provides a comprehensive analysis of the global Long-acting PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long-acting PrEP market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting PrEP.
This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting PrEP market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Cabotegravir
Lenacapavir
Other
Segmentation by Dosing Interval:
Short-interval Injections
Monthly Injections
Quarterly Injections
Segmentation by Drug Properties:
Original Drug
Generic Drug
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Gilead Sciences
ViiV Healthcare
Key Questions Addressed in this Report
What is the 10-year outlook for the global Long-acting PrEP market?
What factors are driving Long-acting PrEP market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Long-acting PrEP market opportunities vary by end market size?
How does Long-acting PrEP break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
82 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Long-acting PrEP by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Long-acting PrEP by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
